Lexeo Therapeutics Reports Q3 2025 Financial Results with Improved Net Loss

Lexeo Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $20.3 million, a significant improvement compared to a net loss of $29.5 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $79.0 million, up from $72.4 million in the prior year. Total operating expenses for the third quarter decreased to $21.6 million from $31.5 million year-over-year, primarily due to reduced research and development costs, which fell to $15.7 million from $23.4 million. General and administrative expenses also decreased to $6.0 million from $8.1 million.

The company’s cash and cash equivalents increased to $41.0 million as of September 30, 2025, compared to $35.0 million at the end of 2024. Lexeo's total assets were reported at $143.8 million, down from $146.9 million at the end of the previous fiscal year. The decrease in total assets was attributed to a reduction in current liabilities, which fell to $17.3 million from $22.8 million, reflecting improved management of accounts payable and accrued expenses.

Strategically, Lexeo has made significant advancements in its clinical programs, particularly with its lead product candidate, LX2006, which is currently in a Phase 1/2 clinical trial for Friedreich's ataxia cardiomyopathy. The company has engaged with the FDA regarding a potential accelerated approval pathway for LX2006, indicating progress in regulatory interactions. Additionally, the company completed a public offering in October 2025, raising approximately $134.6 million in net proceeds, which is expected to support ongoing clinical trials and operational needs.

Operationally, Lexeo has focused on enhancing its manufacturing capabilities, transitioning to a more efficient production process. The company reported that it has successfully dosed participants in its clinical trials, with LX2006 showing promising safety and efficacy data. The company’s employee headcount has also increased, reflecting its commitment to expanding its research and development efforts. Looking ahead, Lexeo anticipates continued investment in its clinical programs and expects to incur significant operating losses as it advances its product candidates through development stages. The company remains focused on securing additional funding to support its long-term growth strategy.